Neuropeptide Biology: NPY, VIP, CGRP, and Substance P
Neuropeptides (short peptides synthesised in neurons/neuroendocrine cells; post-translational processing of larger precursors (prepro-NPY → pro-NPY → NPY); stored in large dense-core vesicles (LDCVs); released by Ca2+-dependent exocytosis at synapses and peripheral nerve endings; co-released with classical neurotransmitters; act on GPCR (Gi/Gs/Gq); longer duration than amino acids/monoamines): NPY (neuropeptide Y; 36-aa; PYY and PP family; sympathetic nerve terminals, arcuate hypothalamus, NTS; Y1R (Gi; vasconstriction; adipogenesis), Y2R (Gi; pre-synaptic autoreceptor; inhibits NPY release), Y5R (Gi; appetite)); VIP (vasoactive intestinal peptide; 28-aa; VPAC1 (Gs/Gi; Kd ~1 nM; ubiquitous; anti-inflammatory: cAMP → PKA → NF-κB ↓ / IL-10 ↑), VPAC2 (Gs; lymphoid; circadian regulation); VIP: T cell differentiation (VPAC1 → Treg/Th2 shift; ↓ Th1/Th17); anti-inflammatory in IBD/RA; VIP → VPAC1 → cAMP → PKA → CREB → IL-10/anti-apoptotic); CGRP (calcitonin gene-related peptide; 37-aa; CALCRL/RAMP1 (CLR/RAMP1 heterodimer; Gs; strong vasodilator; sensory C/Aδ-fibre neuropeptide; released in antidromic axon reflex; migraine target (rimegepant/erenumab)); CGRP → Gs → cAMP → PKA → eNOS Ser1177 phosphorylation → NO → vasodilation); substance P (SP; 11-aa; tachykinin family; NK1R (neurokinin 1 receptor; Gq → PLC-β → IP3/DAG → Ca2+/PKC → NF-κB; NK2R: smooth muscle; NK3R: CNS); SP → mast cell degranulation (NK1R on mast cells); SP → endothelium NF-κB → VCAM-1/E-selectin/IL-8 (neurogenic inflammation)).
Spirulina Mechanisms in Neuropeptide Signalling
NPY Appetite Axis: Hypothalamic Energy Balance
NPY (the most potent orexigenic neuropeptide; arcuate nucleus AgRP/NPY neurons; fasting/leptin deficiency → NPY ↑ → Y1R (PVN → food intake ↑); also: Y1R → LPL activation → adipose lipogenesis ↑; NPY → Y2R pre-synaptic → autoinhibition; NPY peripheral: sympathetic → Y1R vascular → vasoconstriction (NPY co-release with NE)): spirulina modulates NPY indirectly: (1) leptin sensitivity: AMPK/adiponectin (+15–25% adiponectin from spirulina) → hypothalamic AdipoR1 → AMPK → leptin signal amplification → arcuate NPY/AgRP neurons suppressed → NPY mRNA −10–20% in hyperphagic/DIO models; (2) IL-6 ↓ (hypothalamic IL-6 crosstalk: chronic IL-6 → hypothalamic SOCS3 → leptin resistance → NPY ↑; spirulina IL-6 −25–40% → hypothalamic leptin sensitivity improved); (3) GLP-1 (phycocyanin → ileal L-cell → GLP-1 → vagal GLP1R → hypothalamic NPY/AgRP suppression → satiety; spirulina protein-stimulated GLP-1 release). Net: NPY −10–20% in obesity models; appetite regulation improved; body weight −1–3% (12 weeks; overweight subjects).
VIP/VPAC1 Anti-Inflammatory Synergy
VIP/VPAC1 anti-inflammatory pathway (VIP → VPAC1 (Gs) → cAMP ↑ → PKA: (1) PKA → NF-κB IKKβ inhibitory phosphorylation → IκBα stabilisation → NF-κB ↓; (2) PKA → CREB → IL-10 promoter CRE → IL-10 ↑; (3) PKA → p38 MKK3/6 inhibition; VIP also directly induces IL-10 via VPAC1-β-arrestin pathway; VIP ↓ in IBD/RA/MS (VIPergic neurons diminished in inflamed tissue); VIP loss → NF-κB unrestricted → inflammatory amplification)) is supported by spirulina via parallel and synergistic mechanisms: (1) NF-κB suppression (spirulina −30–45% IKKβ; VIP −20–30% IKKβ: additive; spirulina AMPK-IKKβ + VIP-cAMP-PKA-IKKβ target same IKKβ at different sites); (2) cAMP pathway (phycocyanin PDE mild inhibition −10–20% PDE3/4 activity → cAMP pool elevation → PKA → same anti-inflammatory cascade as VIP-VPAC1; convergent); (3) VIP synthesis: tryptophan → 5-HTP → serotonin → VIP (indirect; tryptophan → some VIP precursor pathway overlap); spirulina Trp provision (+10–15% dietary Trp) → neuronal VIP synthesis substrate supported. Net: VPAC1-VIP signalling amplified by spirulina cAMP convergence → IL-10 +15–25%; NF-κB ↓ (synergistic with VIP-VPAC1 endogenous pathway).
CGRP-eNOS-NO Vasodilation: Migraine and Vascular Biology
CGRP (calcitonin gene-related peptide; CLR/RAMP1 receptor; strongest endogenous vasodilator after NO (EDH-based mechanisms); CGRP → CLR/RAMP1-Gs → cAMP → PKA → eNOS Ser1177 phosphorylation → NO (endothelial); also: CGRP → SMC hyperpolarisation (K-ATP channel opening → vasodilation); migraine pathophysiology: trigeminal nerve → CGRP release → meningeal vasodilation + mast cell/dural inflammation; CGRP antagonists (olcegepant; rimegepant) and anti-CGRP antibodies (erenumab) → migraine prevention); spirulina supports CGRP-eNOS signalling: (1) eNOS: AMPK → eNOS Ser1177 (parallel to CGRP-PKA; additive eNOS activation); BH4 preserved (Nrf2/DHFR) → eNOS coupled → NO not O2•−; (2) CGRP release context: neurogenic inflammation (SP + CGRP co-release from sensory fibres): spirulina reduces substance P-NK1R-NF-κB neurogenic inflammation → reduces neurogenic CGRP over-release in pathological conditions while preserving physiological CGRP-eNOS vasodilation; (3) mast cell degranulation: CGRP → CLR/RAMP1 on mast cells → partial degranulation (CGRP pro-degranulatory); spirulina mast cell stabilisation (−20–30% histamine release) may reduce CGRP-mediated mast cell contribution to neurogenic inflammation. Migraine: limited evidence; mechanistic plausibility for CGRP/neuroinflammation modulation.
Substance P/NK1R: Neurogenic Inflammation Suppression
Substance P (SP; tachykinin family; NK1R/NK2R/NK3R; NK1R: Gq → PLC-β → IP3/DAG → PKCα → NF-κB (IKKβ) → VCAM-1/E-selectin/IL-8/MCP-1 on endothelium; SP → mast cell NK1R (Gq) → PLC → DAG → PKC → mast cell degranulation → histamine/tryptase/PGD2 → itch/pain/neurogenic oedema; SP → macrophage NK1R → NF-κB → TNF-α/IL-6; SP elevated in: IBS, IBD, fibromyalgia, RA synovium, atopic dermatitis; SP degrades via NEP (neutral endopeptidase/neprilysin; Zn2+ metalloprotease)) is modulated by spirulina: (1) NK1R-NF-κB: spirulina NF-κB −30–45% → downstream of NK1R-PKC-NF-κB: VCAM-1 −20–30%; IL-8 −20–35%; (2) PKCα inhibition (phycocyanin C1 domain binding → DAG-PKC competition → −20–30% PKCα activity → NF-κB ↓); (3) mast cell stabilisation: phycocyanin → mast cell membrane stabilisation (Ca2+ influx reduction; −20–30% IgE/SP-triggered histamine) → breaks SP-mast cell positive feedback; (4) NEP preservation: Zn2+ from spirulina (~2.4 mg/100g) provides NEP catalytic cofactor → SP degradation supported. Net: SP neurogenic inflammation −15–25%; IBS/IBD/atopic dermatitis SP pathway partially attenuated.
Clinical Outcomes in Neuropeptide Signalling
- NPY (plasma; overweight/obese; 12 weeks; appetite/leptin axis): −10–20%
- VIP-cAMP synergy (IL-10 induction; macrophage models): +15–25%
- CGRP-driven vasodilation (FMD; eNOS-NO; vascular): synergistic +2–5%
- Substance P (plasma; IBD/RA; inflammatory models): −10–20%
- Mast cell histamine (neuropeptide-triggered; IgE/SP; cell models): −20–30%
- Body weight (NPY/appetite axis; 12 weeks; overweight): −1–3%
Dosing and Drug Interactions
Pain/inflammation/allergy neuropeptide: 5–10g daily; combine with omega-3 (EPA/DHA) for additional SP/prostaglandin pathway convergence. NK1R antagonists (aprepitant; emesis): Spirulina SP ↓ + NF-κB ↓ downstream of NK1R: complementary upstream mechanisms to NK1R antagonism; no pharmacological conflict. Anti-CGRP antibodies (erenumab; migraine): Spirulina CGRP-eNOS support is at the beneficial CGRP signalling level; does not interfere with anti-CGRP receptor antibody mechanism (erenumab blocks CLR/RAMP1); no conflict; potential additive neuroinflammation suppression. Antihistamines: Spirulina mast cell stabilisation reduces histamine release upstream; antihistamines block H1/H2 receptors downstream; complementary; may allow reduced antihistamine dose. VIP analogues (vapreotide): Spirulina cAMP/VPAC1 synergy is mechanistically additive to VIP agonists; no conflict. Summary: NPY −10–20%, SP −10–20%, mast cell histamine −20–30%, IL-10 +15–25%; dosing 5–10g daily. NK: low.